Since the publication of an anecdotal case report in 2015 [40] in a patient with IDH-1 wild-type glioblastoma-associated epilepsy, an increasing number of observational small studies exploring the efficacy of PER in BTRE have been published. The gene discussed is IDH1; the disease is glioblastoma.